AtheroGenics, Inc.{AGIX}-nasdaq Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AtheroGenics, Inc.{AGIX}-nasdaq

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: mlrb2113 who wrote (314)	11/1/2007 2:16:04 PM
From: Clarksterh	Read Replies (1) of 332

Sorry. I didn't know we'd talked about bilirubin in statins We have actually discussed liver damage from statins before - I pointed to a comprehensive paper covering all the statin trials and liver effects (either on this board of Yahoo). But no need to apologize - mostly just yanking your chain as this is the second rediscussion of a topic this week (I included a "-g-"). As for Actos and Avandia have caused elevated ALT, I don't remember the details. Would have to refresh - but ALT is not the concern. It is the much rarer bilirubin issue that is the problem. And for those drugs there isn't enough data. Remember that ARISE was huge in patient-years compared to most diabetes trials, and liver issues are rare.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next